NCT05127850Completed
MENCORE-2: Audio Recordings to Improve Decision-making in Advanced Prostate Cancer
Mhealth ElectroNic COnsultation REcording (MENCORE-2): an Implementation Trial to Improve Informed Treatment Decision-making in Men With Advanced Prostate Cancer
Source: ClinicalTrials.gov · Last updated 8 May 2024
Brief summary (registry, in English)
This is a single-arm hybrid implementation trial of men with metastatic castrate-resistant prostate cancer (mCRPC) involving a patient-administered mobile app for consultation audio recordings.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 51 (actual)
- First submitted
- 8 Nov 2021
- Start date
- 22 Mar 2022
- Primary completion date
- 16 Feb 2024
- Lead sponsor
- University of California, San Francisco
- Diseases
- Prostate cancer
- NCT number
- NCT05127850
What you commit to
- Study type: Interventional
- Participants enrolled: 51
- From 22 Mar 2022 to the primary completion date, 16 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior participation in Mobile Health ElectroNic COnsultation REcording (mENCORE) (participants have already received the intervention).
Other illness
- Uncorrectable hearing or visual impairment hindering the ability to perform necessary tasks in the trial.
- Any neurocognitive or psychiatric disorder hindering the ability to perform necessary tasks in the trial.
Other
- Lack of decision-making capacity to provide consent to this trial.
Who the study is looking for
- Metastatic castration-resistant prostate cancer (mCRPC) with progression per any Prostate Cancer Working Group 3 (PCWG3) criterion (Prostate-specific antigen (PSA), clinical, or radiographic)
- Has never received any chemotherapy for prostate cancer.
- Current or prior receipt of at least one androgen-signaling inhibitors (ASI) (abiraterone, enzalutamide, apalutamide, or darolutamide), with progression on it.
- Eligible for docetaxel chemotherapy at any dose level (treating provider's discretion).
- Has an upcoming genitourinary (GU) medical oncology appointment (in-person, telephone, or Zoom video visit) at University of California, San Francisco (UCSF) within 7-60 days of enrollment, during which next-line treatment options are anticipated to be discussed (treating provider's discretion).
- 18 years of age or older.
- Able to read, speak, and write in English (the application is in English only)
- Has access to and ability to use an iOS or Android smartphone or tablet.
- For video visits only: has access to and ability to use a second device (e.g., desktop, laptop, smartphone, tablet, etc.) that will run a Zoom video visit.
- Patient's provider of the upcoming appointment in #5 agrees to be recorded.
- 1\. UCSF GU medical oncology providers (medical doctor (MD), nurse practitioner (NP), or physician's assistant (PA)), regardless of whether their patient was enrolled
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.